Author
Paul A. Carpenter
Other affiliations: Seattle Children's, Seattle Cancer Care Alliance, Fred Hutchinson Cancer Research Center
Bio: Paul A. Carpenter is an academic researcher from University of Washington. The author has contributed to research in topics: Transplantation & Graft-versus-host disease. The author has an hindex of 24, co-authored 52 publications receiving 2174 citations. Previous affiliations of Paul A. Carpenter include Seattle Children's & Seattle Cancer Care Alliance.
Papers published on a yearly basis
Papers
More filters
University of Texas MD Anderson Cancer Center1, University of Washington2, Harvard University3, Johns Hopkins University4, National Institutes of Health5, University of California, San Francisco6, Fred Hutchinson Cancer Research Center7, University of Cincinnati8, University of Minnesota9, University of British Columbia10
TL;DR: Recommendations are provided for prevention of infections, osteoporosis, and steroid myopathy and management of neurocognitive and psychosocial adverse effects related to chronic GVHD and its therapy.
283 citations
TL;DR: It is concluded that imatinib can be safely administered early after myeloablative allogeneic HCT at a dose intensity comparable to that used in primary therapy.
205 citations
Fred Hutchinson Cancer Research Center1, University of Washington2, Rutgers University3, University of Florida4, University of Nebraska Omaha5, Vanderbilt University6, Baylor University Medical Center7, University of Chicago8, University of Michigan9, Stanford University10, Oregon Health & Science University11, University of Minnesota12
TL;DR: Analysis of secondary endpoints showed no evidence of benefit from adding MMF to the systemic regimen first used for treatment of chronic GVHD, and mycophenolate mofetil should not be added to the initial systemic treatment regimen for chronic GvHD.
134 citations
TL;DR: The use of liquid corneal bandage provided by a fluid-ventilated, gas-permeable scleral lens (SL) appears to be safe and effective in patients with severe cGVHD-related KCS refractory to conventional therapies.
117 citations
Memorial Sloan Kettering Cancer Center1, Johns Hopkins University2, University of Washington3, University of Texas Southwestern Medical Center4, University of Pennsylvania5, Alfaisal University6, Mayo Clinic7, University of Texas MD Anderson Cancer Center8, Vanderbilt University9, Sheba Medical Center10, Harvard University11, National Marrow Donor Program12, University of Minnesota13, Children's National Medical Center14, Washington University in St. Louis15, Medical College of Wisconsin16, Baylor College of Medicine17, Fred Hutchinson Cancer Research Center18, University of Miami19, Case Western Reserve University20, University of Texas Medical Branch21, University of Paris22, Stanford University23, Vanderbilt University Medical Center24, National Institutes of Health25, Cornell University26
TL;DR: Advice is provided from experts in the fields of hematopoietic cell transplantation, cellular immunotherapy, and lymphoma regarding key clinical questions pertinent to the utilization of CD19 CAR T for the treatment of NHL.
114 citations
Cited by
More filters
Vanderbilt University Medical Center1, Medical University of Vienna2, University of Minnesota3, National Institutes of Health4, University of Regensburg5, Mayo Clinic6, Brigham and Women's Hospital7, Fred Hutchinson Cancer Research Center8, BC Cancer Agency9, State University of Campinas10, Stanford University11, University of Michigan12, Harvard University13, Johns Hopkins University School of Medicine14
TL;DR: The 2014 NIH consensus maintains the framework of the prior consensus with further refinement based on new evidence, and focuses attention on the causes of organ-specific abnormalities to chronic GVHD.
4,122 citations
Journal Article•
3,097 citations
TL;DR: Hematopoietic stem-cell transplantation was first conceived more than 50 years ago, but problems associated with transplanting a nonsolid organ and modulating the immune response had to be solved before the procedure could be used clinically as mentioned in this paper.
Abstract: Hematopoietic stem-cell transplantation, which is used to treat both malignant and nonmalignant conditions, was first conceived more than 50 years ago, but problems associated with transplanting a nonsolid organ and modulating the immune response had to be solved before the procedure could be used clinically. This review summarizes background information about hematopoietic stem-cell transplantation and discusses the current role of the procedure.
2,180 citations
TL;DR: The understanding of the risk factors and causes of GHVD, the cellular and cytokine networks implicated in its pathophysiology, and current strategies to prevent and treat the disease are reviewed.
2,083 citations